Covering a wide variety of products, tools, and technologies, the Wellcome Genome Campus supports globally important partnerships and projects in genomics and computational biology.
AlphaFold is an AI system developed by DeepMind that predicts a protein’s 3D structure from its amino acid sequence. It regularly achieves accuracy competitive with experiments. DeepMind and EMBL’s European Bioinformatics Institute (EMBL-EBI) have partnered to create AlphaFold DB to make these predictions freely available to the scientific community.
Flatworm Functional Genomics Initiative (FUGI)
A consortium funded by a Wellcome Trust Strategic Award to develop game-changing research tools for the study and manipulation of parasitic flatworm species responsible for the devastating diseases echinococcosis (hydatid disease) and schistosomiasis (bilharzia).
Genomics Surveillance Unit
The goal of the Genomic Surveillance Unit (GSU) is to support partners around the world to achieve their vision for genomic surveillance as a practical tool for local infectious disease control and pandemic preparedness.
100,000 Genomes Project
The 100,000 Genomes Project sequenced genomes from around 70,000 National Health Service (NHS) patients, focusing on individuals with rare diseases or cancer. The project was managed by Genomics England, an organisation established by the Department of Health specifically for this purpose.
Human Cell Atlas
Aiming to map every cell type in the human body, the Human Cell Atlas (HCA) will transform our understanding of biology and disease, and could lead to major advances in the way illnesses are diagnosed and treated.
The Mutographs project is a Cancer Research UK ‘Grand Challenge’ project that hopes to uncover some of the unknown causes of cancer. The project will do this by searching for tell-tale signatures that are left in DNA by factors linked to cancer development.
ELIXIR unites Europe’s leading life science organisations in managing and safeguarding the increasing volume of data being generated by publicly funded research. It coordinates, integrates and sustains bioinformatics resources across its member states and enables users in academia and industry to access services that are vital for their research.
The TEHDAS Joint Action project develops European principles for the secondary use of health data. TEHDAS is being carried out by 25 European countries and co-ordinated by the Finnish Innovation Fund, Sitra.
Open Targets is a unique partnership between the Wellcome Sanger Institute and EMBL-EBI and pharmaceutical companies including GSK, Takeda, Sanofi and Celgene. It brings to bear the most cutting-edge genomic research and computer science to more precisely identify drug targets early on in drug development.
HipSci brought together diverse constituents in genomics, proteomics, cell biology and clinical genetics to create a UK national induced pluripotent stem (iPS) cell resource and use it to carry out cellular genetic studies.
A trusted navigational tool for precision oncology. Cancer genomics is growing exponentially. Our expert curation process captures, analyses, and displays the wealth of data in world-renowned databases.
Global Alliance for Genomics in Health
The Global Alliance for Genomics and Health (Global Alliance) was formed to help accelerate the potential of genomic medicine to advance human health. It brings together over 400 leading institutions working in healthcare, research, disease advocacy, life science, and information technology.
International Common Disease Alliance (ICDA)
International Common Disease Alliance (ICDA) aims to improve prevention, diagnosis, and treatment of common diseases by accelerating discovery from genetic maps to biological mechanisms to physiology and medicine, to benefit people around the world.
MalariaGEN is a data-sharing network with partners in over 40 countries. It is committed to working collaboratively to build and share large genomic data resources, to study malaria epidemiology, and translate these into accessible resources for malaria control.
European Bank for Induced Pluripotent Stem Cells – EbiSC
EBiSC has been designed to address the increasing demand for quality-controlled, disease-relevant, research-grade iPSC lines, data and cell services. It is a centralised, not-for-profit iPSC bank providing researchers across academia and industry with access to scalable, cost-efficient and consistent, high quality tools for new medicines development.
Aquatic Symbiosis Genomics
The Aquatic Symbiosis Genomics project, jointly funded by the Wellcome Sanger Institute and the Gordon and Betty Moore Foundation, seeks to provide the genomic foundations needed by scientists to answer key questions about the ecology and evolution of symbiosis in marine and freshwater species, where at least one partner is a microbe.
The BIOSCAN project aims to study the genetic diversity of 1,000,000 flying insects from across the UK. Insects from 100 sites will be collected on a monthly basis for five years by project partners and then analysed at the Sanger using DNA barcoding.
Human Cell Models initiative
The Human Cancer Models Initiative is an international effort to generate, genomically characterise and annotate the next-generation of cancer cell models as a resource for the scientific community. The Wellcome Sanger Institute is a founding member of this initiative and is actively contributing towards the cancer cell model collection.
Atlas of Variant Effects Alliance
Precision medicine at nucleotide resolution. The vision of the Alliance is to create comprehensive variant effect maps for important regions of human and human pathogen genomes that could ultimately assist in the diagnosis, prognosis and treatment of disease.
Earth Biogenome project
The Earth BioGenome Project (EBP), a moonshot for biology, aims to sequence, catalogue and characterize the genomes of all of Earth’s eukaryotic biodiversity over a period of ten years.